Toll Free: 1-888-928-9744

Acne Vulgaris - Pipeline Review, H2 2017

Published: Oct, 2017 | Pages: 201 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Acne Vulgaris - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acne Vulgaris - Pipeline Review, H2 2017, provides an overview of the Acne Vulgaris (Dermatology) pipeline landscape.

Acne vulgaris is a chronic skin disease involving blockage and inflammation of pilosebaceous follicles. Symptoms include crusting of skin bumps, cysts, papules (small red bumps), scarring of the skin and redness around the skin eruptions. Risk factors include adolescence, hair gels or oil-based cosmetics, sports equipment such as helmet straps rubbing and occluding skin. Treatment includes antibiotics. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acne Vulgaris - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Acne Vulgaris (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acne Vulgaris (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 12, 20, 9, 1, 17, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Acne Vulgaris (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acne Vulgaris (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Acne Vulgaris (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acne Vulgaris (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acne Vulgaris (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Acne Vulgaris (Dermatology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acne Vulgaris (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acne Vulgaris (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 Introduction 5 Acne Vulgaris - Overview 6 Acne Vulgaris - Therapeutics Development 7 Acne Vulgaris - Therapeutics Assessment 18 Acne Vulgaris - Companies Involved in Therapeutics Development 28 Acne Vulgaris - Drug Profiles 46 Acne Vulgaris - Dormant Projects 172 Acne Vulgaris - Discontinued Products 177 Acne Vulgaris - Product Development Milestones 178 Appendix 193
List of Tables
Number of Products under Development for Acne Vulgaris, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Acne Vulgaris - Pipeline by 3SBio Inc, H2 2017 Acne Vulgaris - Pipeline by Almirall SA, H2 2017 Acne Vulgaris - Pipeline by Biomar Microbial Technologies, H2 2017 Acne Vulgaris - Pipeline by BioPharmX Inc, H2 2017 Acne Vulgaris - Pipeline by Blueberry Therapeutics Ltd, H2 2017 Acne Vulgaris - Pipeline by Braintree Laboratories Inc, H2 2017 Acne Vulgaris - Pipeline by Brickell Biotech Inc, H2 2017 Acne Vulgaris - Pipeline by Cassiopea SpA, H2 2017 Acne Vulgaris - Pipeline by Celtaxsys Inc, H2 2017 Acne Vulgaris - Pipeline by Common Pharma Inc, H2 2017 Acne Vulgaris - Pipeline by Cutanea Life Sciences Inc, H2 2017 Acne Vulgaris - Pipeline by Deltanoid Pharmaceuticals Inc, H2 2017 Acne Vulgaris - Pipeline by Dermira Inc, H2 2017 Acne Vulgaris - Pipeline by Eligo Bioscience SAS, H2 2017 Acne Vulgaris - Pipeline by ELORAC Inc, H2 2017 Acne Vulgaris - Pipeline by Ensol Biosciences Inc, H2 2017 Acne Vulgaris - Pipeline by Foamix Pharmaceuticals Ltd, H2 2017 Acne Vulgaris - Pipeline by Galderma SA, H2 2017 Acne Vulgaris - Pipeline by Helix BioMedix Inc, H2 2017 Acne Vulgaris - Pipeline by Hovione FarmaCiencia SA, H2 2017 Acne Vulgaris - Pipeline by Innovation Pharmaceuticals Inc, H2 2017 Acne Vulgaris - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017 Acne Vulgaris - Pipeline by LEO Pharma A/S, H2 2017 Acne Vulgaris - Pipeline by Melinta Therapeutics Inc, H2 2017 Acne Vulgaris - Pipeline by Novabiotics Ltd, H2 2017 Acne Vulgaris - Pipeline by Novan Inc, H2 2017 Acne Vulgaris - Pipeline by Novartis AG, H2 2017 Acne Vulgaris - Pipeline by Paratek Pharmaceuticals Inc, H2 2017 Acne Vulgaris - Pipeline by Pfizer Inc, H2 2017 Acne Vulgaris - Pipeline by Phagelux Inc, H2 2017 Acne Vulgaris - Pipeline by Phosphagenics Ltd, H2 2017 Acne Vulgaris - Pipeline by Photocure ASA, H2 2017 Acne Vulgaris - Pipeline by Promius Pharma LLC, H2 2017 Acne Vulgaris - Pipeline by Provectus Biopharmaceuticals Inc, H2 2017 Acne Vulgaris - Pipeline by Realm Therapeutics Plc, H2 2017 Acne Vulgaris - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2017 Acne Vulgaris - Pipeline by Sol-Gel Technologies Ltd, H2 2017 Acne Vulgaris - Pipeline by Sun Pharmaceutical Industries Ltd, H2 2017 Acne Vulgaris - Pipeline by Taro Pharmaceutical Industries Ltd, H2 2017 Acne Vulgaris - Pipeline by Thesan Pharmaceuticals Inc, H2 2017 Acne Vulgaris - Pipeline by Valeant Pharmaceuticals International Inc, H2 2017 Acne Vulgaris - Pipeline by Vyome Biosciences Pvt Ltd, H2 2017 Acne Vulgaris - Pipeline by XBiotech Inc, H2 2017 Acne Vulgaris - Dormant Projects, H2 2017 Acne Vulgaris - Dormant Projects, H2 2017 (Contd..1), H2 2017 Acne Vulgaris - Dormant Projects, H2 2017 (Contd..2), H2 2017 Acne Vulgaris - Dormant Projects, H2 2017 (Contd..3), H2 2017 Acne Vulgaris - Dormant Projects, H2 2017 (Contd..4), H2 2017 Acne Vulgaris - Discontinued Products, H2 2017



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify